Data / Form D filings / Nasus Pharma Ltd
Nasus Pharma Ltd: Form D filing
Nasus Pharma Ltd, a biotechnology company in Tel Aviv, Israel, filed a Form D with the SEC in 2026. The latest, on February 25, 2026, reports $15 million sold of a $15 million offering to 15 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 34 YITZHAK SADEH ST, Tel Aviv, Israel, 62747
- Phone
- +972.3.573.6632
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Israel
- Revenue range
- No Revenues
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2029039
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Feb 25, 2026 | New notice | $15,000,040 | $15,000,040 | 15 | Feb 10, 2026 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Dan Teleman | Executive Officer, Director | Chief Executive Officer |
| Eyal Rubin | Executive Officer | Chief Financial Officer and Executive Vice President |
| Udi Gilboa | Director | |
| Dalia Megiddo | Executive Officer, Director | Chief Development Officer and Chief Medical Officer |
| Ronnie Hershman | Director | |
| David Silberman | Director | |
| Sharon Shacham | Director | |
| Isaac Israel | Director |
Every Form D from the week of Feb 23, 2026 · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Nasus Pharma Ltd reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.